Active Biotech AB Interim report January - June 2015

August 7, 2015 08:30 (CEST)

· Operations focused on the laquinimod projects and organization adjusted accordingly

Laquinimod
· The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS) is fully enrolled and results are expected in 2017
· The first patient was enrolled for the ARPEGGIO Phase II study, which will evaluate laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
· The Phase II study LEGATO-HD into Huntington's disease is proceeding according to plan
· Laquinimod presented by Teva at the AAN Annual Meeting on April 18-25, 2015

Tasquinimod     
· Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod significantly reduced the risk of radiographic cancer progression compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28).
· Further development of tasquinimod discontinued and the collaboration agreement with Ipsen terminated
 
ISI          
· Only commercial activities will be conducted from 2016

Financial summary

MSEK   April - June     Jan. - June   Jan. - Dec.
  2015 2014   2015 2014   2014  
                 
Net sales 3.2 2.7   6.1 4.9   10.4  
                 
Operating loss -70.1 -57.9   -127.5 -117.2   -228.5  
                 
Loss for the period -71.4 -57.7   -129.3 -117.9   -231.5  
                 
Loss per share (SEK) -0.79 -0.77   -1.44 -1.57   -3.02  
                 
Cash and cash equivalents        186.6 227.7   328.5  

 
For further information, please contact: 

 Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95
  
 Hans Kolam, CFO
 Tel: +46 (0)46 19 20 44
  
 The report is also available at www.activebiotech.com

Active Biotech AB
Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

Active Biotech AB Interim report January - June 2015